Yahoo
NasdaqCM - BOATS Real Time Price USD

Zhengye Biotechnology Holding Limited (ZYBT)

1.3000 -0.1300 (-9.09%)
At close: October 30 at 4:00:00 PM EDT
1.3100 +0.0100 (+0.77%)
Overnight: 11:30:37 PM EST
Chart Range Bar
Loading chart for ZYBT
Chart does not reflect overnight price.
  • Previous Close 1.4300
  • Open 1.1700
  • Bid 1.6700 x 200
  • Ask 1.6000 x 100
  • Day's Range 1.1700 - 1.4000
  • 52 Week Range 0.6160 - 8.0100
  • Volume 122,943
  • Avg. Volume 2,001,893
  • Market Cap (intraday) 61.609M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

www.jlzybio.com

269

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZYBT
13.04%
S&P 500 (^GSPC)
10.73%

1-Year Return

ZYBT
44.68%
S&P 500 (^GSPC)
11.11%

3-Year Return

ZYBT
65.52%
S&P 500 (^GSPC)
81.91%

5-Year Return

ZYBT
65.52%
S&P 500 (^GSPC)
64.59%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -59.97%

  • Return on Assets (ttm)

    -9.48%

  • Return on Equity (ttm)

    -25.17%

  • Revenue (ttm)

    116.36M

  • Net Income Avi to Common (ttm)

    -69.78M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    51.89M

  • Total Debt/Equity (mrq)

    24.48%

  • Levered Free Cash Flow (ttm)

    39.58M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: